Stephane Bancel

Stephane Bancel is the Chief Executive Officer of Moderna, a pharmaceutical company. He is currently newsworthy due to the recent developments surrounding Moderna's application for FDA approval of its flu vaccine. The FDA initially declined to review Moderna's application, raising concerns despite Bancel stating the rejection letter cited no safety or efficacy issues. This refusal occurred amidst a backdrop of declining COVID-19 vaccine sales, contributing to a drop in Moderna's stock value in 2025. However, in a subsequent development, the US government announced it would review Moderna's flu vaccine application after initially declining. The company remains optimistic about the vaccine's potential availability later in 2026. Bancel's leadership is crucial as Moderna navigates these regulatory challenges and seeks to diversify its vaccine portfolio beyond COVID-19.